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Abstract	Post-traumatic	stress	disorder	(PTSD)	is	a	mental	health	condition	that	affects	people	after	instances	of	severe	emotional	trauma.	Research	suggests	that	oxytocin	treatment	decreases	PTSD	symptoms.	This	study	served	to	evaluate	the	efficacy	of	intranasal	oxytocin	pre-treatment	on	symptoms	related	to	PTSD.	The	hypotheses	are	that	oxytocin	will	decrease	fear	and	anxiety,	and	increase	reward-seeking	behaviors.	Sprague	Dawley	rats	were	assigned	to	three	groups	(Control,	Stress,	
Oxytocin,	and	Oxytocin+Stress;	n=6	per	group)	to	conduct	this	experiment.	Prior	to	foot	shock	treatment,	rats	were	trained	to	expect	a	food	reward	(Kellogg’s	Froot	Loops)	in	an	open	field	enclosure.	Subsequently,	the	Oxytocin	and	the	
Oxytocin+Stress	groups	were	pre-treated	with	intranasal	oxytocin	and	then	the	
Stress	and	Oxytocin+Stress	groups	were	exposed	to	an	inescapable	foot	shock	(a	model	PTSD	inducing	stressor).	After	oxytocin	and	shock	treatments,	rats	underwent	various	behavioral	tests:	re-exposure	to	the	shock	chamber	to	assess	fear,	elevated	O-maze	to	assess	anxiety,	and	food	reward	trials	in	the	open	field	enclosure	to	assess	reward-seeking	behavior.	The	oxytocin	treatment	decreased	fear	related	symptoms	upon	re-exposure	to	the	fear	conditioning	chamber;	both	colonic	motility	and	freezing	time	were	lower	in	the	Oxytocin+Stress	group	compared	to	the	Stress	group.	The	foot	shock	model	failed	to	produce	significant	behavioral	changes	related	to	anxiety	and	reward-seeking	behavior	between	the	
Control	and	Stress	groups.	
	
Background	and	Significance	
PTSD	Post-traumatic	stress	disorder	(PTSD)	is	a	mental	health	condition	that	affects	people	after	instances	of	severe	emotional	or	physical	trauma.	Diagnostic	criteria	are	complex	and	symptoms	vary	between	individuals,	but	include	emotional	distress,	physical	reactivity,	avoidance	of	trauma	related	reminders,	decreased	interest	in	activities,	and	difficulty	experiencing	positive	affect	(American	Psychiatric	Association,	2013).	It	is	estimated	that	between	8.3%	and	9.4%	percent	of	the	United	States	population	develops	diagnosable	PTSD	in	their	lifetime	(Kilpatrick	et	al.,	2013).		
Rodent	Model	of	PTSD	
While	previous	researchers	have	used	corticosterone	administration	to	induce	symptoms	of	PTSD	in	rodents	(Levy	et	al.,	2001),	more	recently	a	fear-conditioning	paradigm	using	chronic	electric	foot	shock	(described	in	the	Methods	section)	has	been	developed	to	induce	PTSD-like	symptoms	in	a	rat	model	(Sahraei	et	al.,	2012;	Yu	et	al.,	2012;	Gao	et	al.,	2014)	.	This	paradigm	produces	behavioral	changes	in	rats	such	as	fear	and	anxiety,	which	are	known	to	be	associated	with	PTSD.	Fear	in	rats	is	commonly	assessed	by	increased	freezing	behavior	(Fanselow,	1994;	Sahraei	et	al.,	2012;	Yu	et	al.,	2012;	Gao	et	al.,	2014).	Freezing	is	defined	as	motionless	periods	upon	re-exposure	to	the	previously	traumatizing	source	of	stimuli,	the	foot	shock	chamber	(Yu	et	al.,	2012;	Gao	et	al.,	2014),	and	is	a	hallmark	of	stress-induced	behavioral	changes	in	rodents.	Another	assessment	of	fear	in	rodents	is	increased	defecation	when	re-exposed	to	fear	related	stimuli	(Lester	et	al.,	
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1968;	Gao	et	al.,	2011).	Increased	defecation,	often	referred	to	as	“colonic	motility”,	is	a	measure	highly	sensitive	to	psychological	stress	(Stam	et	al.,	1995).	Colonic	motility	is	thought	to	be	regulated	by	the	release	of	corticotropin-releasing	hormone	caused	by	stressful	events	(Verleye	&	Gillardin,	2004).		Anxiety	is	commonly	manifested	and	measured	in	rodents	as	decreased	locomotion	(Fernandes	et	al.,	1999;	Prut	&	Belzung,	2002)	and	increased	time	in	enclosed	spaces	(Pellow	et	al.,	1985;	Shepherd	et	al.,	1994;	Ennaceur	et	al.,	2006).	Many	different	methods	have	been	used	to	assess	anxiety	in	rodents	and	include	the	open-field	test,	elevated	plus-maze,	and	elevated	O-maze	(reviewed	in	Sestakova	et	al.,	2013).	The	open-field	test	is	the	simplest	and	longest	used	anxiety	test	for	rats,	dating	back	to	1930’s	(Hall	and	Ballachey,	1932).	While	specific	requirements	of	the	open-field	are	not	standardized,	in	general	it	consists	of	an	open	area	in	which	ambulation	can	be	observed	(Walsh	and	Cummings,	1976).	The	test	measures	locomotion	and	propensity	to	explore;	lower	amounts	of	locomotion	and	exploration	correlate	to	higher	levels	of	anxiety	(Perals	et	al.,	2017;	Prut	and	Belzung	2003).	The	elevated	plus-maze	is	a	four-armed	maze	that	is	raised	off	the	ground	by	legs.	Each	arm	is	connected	at	a	center	platform.	Two	arms	of	the	plus-maze	have	high	walls	and	the	other	two	arms	do	not	have	walls.	The	time	spent	in	the	walled	areas	is	associated	with	anxious	behavior	(Pellow	et	al.,	1984;	Rodgers	and	Dalvi,	1997)	as	the	rat	is	thought	to	be	avoiding	the	novelty	of	the	open	area	(Dawson	&	Tricklebank,	1995).	The	elevated	O-maze	(or	elevated	zero-maze)	was	developed	as	an	improvement	to	the	elevated	plus-maze.	The	concepts	of	the	plus-maze,	such	as	height	off	the	ground	and	the	open	versus	closed	areas,	remain	the	
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same	but	the	O-maze	forms	a	continuous	circle	(or	zero)	with	alternating	quadrants	of	open	(no	walls)	and	closed	(walled	off)	areas.	This	configuration	allows	for	easier	exploration	between	maze	sections	since	there	are	no	corners	and	the	rats	do	not	have	to	turn	around	while	continuing	to	move	about	the	maze	(Shepherd	et	al.,	1994).	It	has	been	suggested	that	the	elevated	O-maze	produces	more	consistent	results	over	time	(Tucker	&	McCabe,	2017);	however,	the	results	of	the	elevated	O-maze	are	diminished	by	daily	re-exposure	(Cook	et	al.,	2001).		 Anhedonia	(the	decrease	in	the	capacity	to	feel	pleasure)	has	relatively	recently	been	incorporated	into	the	diagnostic	criteria	of	PTSD	(Stein	et	al.,	2014).	It	is	thought	that	PTSD	may	be	associated	with	reward-seeking	impairments.	While	the	response	is	varied,	there	seems	to	be	an	overall	decrease	in	reward	anticipation,	approach	(or	wanting),	and	hedonic	responses	to	reward	(Nawijn	et	al.,	2015).	This	symptom	of	PTSD,	observed	in	humans,	has	not	yet	been	investigated	in	the	rodent	model.	Reward	seeking	in	rodents	is	most	commonly	assessed	by	the	use	of	an	operant	box	(Dingess	et	al.,	2017;	Piantadosi	et	al.,	2017).	Since	operant	boxes	are	currently	not	available	in	our	lab,	one	of	the	goals	of	this	study	was	to	investigate	the	impact	of	stress	on	the	reward-seeking	behavior	in	an	open	field	circular	enclosure	(described	in	the	Methods	section).	Furthermore,	a	recent	study	conducted	by	Nawijn	et	al.	(2016)	suggests	that	oxytocin	treatment	in	humans	with	PTSD	appears	to	impact	the	brain	regions	involved	in	reward	processing.	Therefore,	another	goal	of	this	study	was	to	investigate	the	impact	of	oxytocin	on	PTSD-related	behaviors	(i.e.,	fear,	anxiety,	and	reward-seeking).	
Oxytocin	
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Oxytocin	is	a	neurohormone	produced	by	neurons	of	the	paraventricular	and	supraoptic	nuclei	in	the	hypothalamus.	It	is	associated	with	many	functions	of	the	body	including	human	emotion	and	motivation	(Love,	2014).	Administered	after	traumatization,	oxytocin	has	been	shown	to	reduce	symptoms	associated	with	PTSD	(i.e.,	fear	and	anxiety)	in	both	rodent	(Missig	et	al.,	2010;	Ayers	et	al.,	2011;	Zoicas	et	al.,	2014;	Janezic	et	al.,	2016;	Sack	et	al.,	2017)	and	human	clinical	trials	(Bakermans-Kranenburg	&	Van	IJzendoorn,	2009;	Acheson	et	al.,	2013;	Frijiling	et	al.,	2014).		Oxytocin	is	a	neuropeptide	that	directly	interacts	with	oxytocin	receptors	in	specific	parts	of	the	central	nervous	system,	as	such	it	is	considered	a	neuromodulator	in	brain	regions	associated	with	fear,	aggression	and	social	behaviors	(Febo	&	Ferris,	2014;	Heinrichs	&	Domes,	2008).	Oxytocin	receptors	are	expressed	in	the	amygdala,	which	is	an	area	of	the	brain	intimately	involved	in	processing	of	emotion	and	cognition	(reviewed	in	Phelps,	2006).	Furthermore,	oxytocin	receptors	are	also	found	in	reward	processing	areas	of	the	brain	(Febo	and	Ferris,	2014)	including	the	ventral	tegmental	area	and	the	nucleus	accumbens	(Wise	and	Bozarth,	1987;	Nicola,	2016).	Hypothalamic	oxytocin	neurons	have	direct	axonal	connections	to	the	amygdala,	ventral	tegmental	area,	and	nucleus	accumbens	and	are	thought	to	directly	modulate	the	activity	of	these	brain	regions	(Bethlehem	et	al.,	2012).	In	addition	to	its	direct	effects	on	brain	regions	associated	with	the	processing	of	emotions	and	motivation,	oxytocin	also	interacts	with	the	hypothalamic-pituitary-adrenal	(HPA)	axis.	This	endocrine	feedback	system	is	
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implicated	in	stress	reactions	as	well	as	regulating	many	body	processes	(Bhatnagar	et	al.,	2006;	Stranahan	et	al.,	2008;	Hall	et	al.,	2012;	Daskalakis	et	al.,	2013).	The	HPA	axis	can	be	modified	permanently	by	early	childhood	trauma,	rendering	it	hyper	reactive	(van	Bodegom	et	al.,	2017).	Oxytocin	has	been	shown	to	inhibit	stress	responses	associated	with	the	HPA	axis	such	as	corticosterone	release	(Windle	et	al.,	1997;	Heinrichs	et	al.,	2003;	De	Kloet	et	al.,	2006).	As	a	natural	mechanism,	oxytocin	offers	protection	to	stress	associated	with	the	HPA	axis	in	postpartum,	breastfeeding	mothers	(Cox	et	al.,	2014).	Oxytocin	levels	rise	peripherally	following	stressful	incidents	and	higher	oxytocin	levels	correspond	to	faster	recovery	from	stress	related	symptoms	(Engert	et	al.,	2016).	Therefore,	oxytocin	treatment	could	potentially	provide	neuroprotection	during	stressful	events.	
Prophylaxis	
Various	pharmaceutical	and	psychosocial	interventions	have	been	studied	as	potential	preventative	treatments	for	PTSD	(reviewed	in	Baker	et	al.,	2009;	Daskalakis	et	al.,	2013).	Most	preventative	measures	that	have	been	explored	fall	into	the	category	of	“early	intervention”	in	which	treatment	is	given	after	the	traumatic	event,	but	prior	to	development	of	PTSD	related	symptoms	(reviewed	in	Birur	et	al.,	2017).	Multiple	drugs	have	been	studied	as	potential	preventative	treatments	for	PTSD	(Vaiva	et	al.,	2003;	Baker	et	al.,	2009;	Daskalakis	et	al.,	2013,	Morena	et	al.,	2017).	However,	the	efficacy	of	oxytocin	as	a	prophylactic,	or	preventative,	treatment	has	been	minimally	explored	in	humans	(Frijling	et	al.,	2014;	van	Zuiden	et	al.,	2017)	and	there	is	a	dearth	of	research	with	rodents	
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(Renicker	et	al.,	2015).	Oxytocin	may	offer	the	same	neuroprotective	benefits	of	other	treatments	(Vaiva	et	al.,	2003;	Baker	et	al.,	2009;	Daskalakis	et	al.,	2013,	Morena	et	al.,	2017)	without	the	risks	associated	with	long-term	treatment,	including	antidiuresis	and	hyponatremia	(Baker	et	al.,	2009).		
	
	
Intranasal	Administration	
Intranasal	administration	of	oxytocin	is	an	effective	therapeutic	delivery	method	in	humans	(Fischer-Shofty	et	al.,	2010;	Guastella	et	al.,	2010;	Acheson	et	al.,	2013;	Nawijn	et	al.,	2016).	While	the	mechanisms	are	not	clearly	understood,	intranasal	oxytocin	administration	produces	“clear	and	specific	changes	in	neural	activation”	(Veening	&	Olivier	2013)	and	has	been	shown	to	increase	levels	of	oxytocin	in	cerebral	spinal	fluid	(Stevens	et	al.	2013,	Streipens	et	al.,	2013).	Intranasal	oxytocin	administration	has	also	been	shown	to	impact	specific	brain	regions	considered	‘social’	regions	(Bethlehem	et	al.,	2012).	Oxytocin	is	a	very	small	peptide	of	nine	amino	acids	(a	nonapeptide)	and	is	believed	to	at	least	partially	pass	through	the	blood	brain	barrier	(Ermisch	et	al.,	1985).	Oxytocin	administrated	intranasally	is	thought	bypass	the	blood	brain	barrier	(Talegaonkar	&	Mishra	2004)	and	has	been	shown	to	produce	higher	levels	of	oxytocin	in	the	brain	than	peripheral	administration	(Neumann	et	al.,	2013).	Additionally,	peripheral	oxytocin	may	have	different	effects	on	stress	than	oxytocin	delivered	directly	into	the	central	nervous	system	via	intranasal	administration.	One	study	found	that	increased	
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plasma	oxytocin	levels	correlate	to	increased	cortisol	levels	(Taylor	et	al.,	2006),	although	causation	was	not	implied.	Research	suggesting	that	intranasal	administration	of	oxytocin	directly	and	effectively	impacts	brain	function	warrants	investigation	into	its	potential	therapeutic	effects	on	conditions	such	as	PTSD.	
	 The	purpose	of	this	study	was	to	test	the	hypothesis	that	prophylactic	oxytocin	treatment	with	decrease	PTSD	related	symptoms	in	a	rat	model,	specifically	decreasing	fear	and	anxiety	related	behaviors	and	increasing	reward-seeking	behaviors.		
Methods	
		 Twenty-four	male	Sprague	Dawley	rats	were	randomly	assigned	to	four	groups	(n=6,	per	group):	1.	Control	group	(no	shock	and	no	oxytocin	treatment),	2.	
Stress	group	(exposed	to	shock	and	no	oxytocin	treatment),	3.	Oxytocin	group	(no	shock	and	treated	with	oxytocin),	and	4.	Oxytocin+Stress	group	(treated	with	oxytocin	and	exposed	to	shock).	For	practical	purposes	the	rats	were	split	into	3	cohorts,	testing	n=2	rats	from	each	treatment	group	at	a	time	(2-3	month	timeframe).		
General	housing	
Rats	were	housed	individually	to	most	effectively	monitor	food	consumption	during	behavioral	tasks.	Rats	were	housed	in	a	polysulfone	filter	top	cage.	Cages	contained	corn	cob	bedding,	PVC	pipe,	and	water	supplied	ad	libitum.	“Harlan	2018”	food	was	provided	ad	libitum,	except	during	the	weeks	of	food	deprivation	
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(described	below).	All	rats	were	housed	in	the	same	room	kept	at	a	temperature	of	22	+	1°C,	and	a	humidity	of	23-33%	with	a	12	hour	light/dark	cycle.	
Reward	Training	
Prior	to	oxytocin	treatment	and	fear	conditioning	(foot	shock),	all	rats	were	pre-trained	to	expect	and	retrieve	a	food	reward	(Kellogg’s	Froot	Loop)	in	a	circular	open	field	enclosure	(3-ft	x	3-ft,	1-ft	walls)	with	a	reward	delivery	tube	at	one	end	(Fig.	1).	For	one	week,	rats	were	habituated	to	the	enclosure	by	allowing	them	to	roam	freely	for	a	minimum	of	5-10	minutes	a	day	(Monday-Friday),	three	Froot	Loops	were	delivered	into	the	chamber	during	this	time	to	familiarize	them	to	the	reward	delivery	procedure	and	assess	their	interest	in	the	food	reward.	For	the	next	2-3	weeks	rats	were	food	restricted,	placed	in	a	start	box	in	the	open	field	enclosure	and	3	Froot	Loops	were	delivered	independently	into	the	reward-seeking	area	(Fig.	1).	For	each	reward-seeking	trial,	the	rat	was	placed	in	the	start	box,	the	Froot	Loop	was	delivered	and	the	start	box	door	was	opened	manually	by	the	experimenter.	The	time	for	the	rat	to	retrieve	the	reward	(within	a	minute	of	reward	delivery)	was	monitored	and	recorded	as	an	assessment	of	their	“reward-seeking”	behavior.		
Food	Deprivation	
After	the	first	week	of	habituation,	rats	were	food	restricted	on	Monday-Friday	and	fed	ad	libitum	on	the	weekends.	Rats	were	weighed	daily	while	food	restricted	and	given	an	amount	of	food	that	correlated	to	their	weight	change.	Rats	who	lost	0-5	grams,	or	gained	weight	were	fed	one	half	of	a	food	pellet,	those	who	lost	6-10	grams	were	fed	1	pellet,	rats	who	lost	11-15	grams	were	fed	1.5	pellets	and	
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those	who	lost	15	grams	or	more	were	fed	2	pellets.	Rats	who	drop	below	80%	of	their	starting	weight	during	food	restriction	would	have	been	fed	ad	libitum,	though	there	were	no	instances	of	this	in	our	study.		
Oxytocin	Administration	
Rats	were	lightly	anesthetized	with	isoflurane	to	calm	them	sufficiently	to	allow	for	intranasal	administration.	The	Oxytocin+Stress	and	the	Oxytocin	groups	were	treated	with	intranasal	oxytocin	at	0.1	µL/kg,	30	minutes	prior	to	fear	conditioning	(described	below)	based	on	Ayers	et	al.	(2011)	procedure.	The	Control	and	Stress	groups	were	administered	an	equivalent	amount	of	saline.	The	rats	were	then	assessed	for	fear,	anxiety	and	reward-seeking	behaviors	(described	below).		
Fear	Conditioning	
The	Stress	and	Oxytocin+Stress	groups	were	exposed	to	an	electric	foot-shock	paradigm	(used	as	a	model	for	a	PTSD	inducing	stressor;	Gao	et	al,	2014).	Over	a	period	of	three	days,	rats	in	these	groups	were	exposed	to	foot	shock	twice	daily.	They	were	placed	into	the	fear-conditioning	chamber	twice	daily	and	given	20	inescapable	foot	shocks	(8	mA	intensity,	3	second	duration,	10	second	intervals	between	shocks;	similar	to	Gao	et	al.,	2014).	
Behavioral	Assessments			 After	oxytocin	and	shock	treatments,	all	rats	were	reintroduced	to	the	shock	chamber	to	assess	behaviors	related	to	fear	(i.e.,	time	motionless	and	defecation),	run	on	an	elevated	O-maze	(Fig.	2)	to	assess	behaviors	related	to	increased	anxiety	
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(i.e.,	decrease	in	time	spent	in	the	open	segments	of	the	maze),	and	given	three	reward	delivery	trials	in	the	open	field	enclosure	to	assess	reward-seeking	behavior	(i.e.,	time	to	retrieve	reward).		Rats	were	placed	in	the	shocking	chamber	for	five	minutes,	but	not	shocked,	to	observe	fear	related	behaviors.	Fear	is	often	expressed	and	measured	by	an	increase	in	freezing	time	(defined	as	the	absence	of	all	movements	except	for	those	related	to	respiration;	Gao	et	al.	2014)	and	by	an	increase	in	fecal	production	(Gao	et	al.,	2011)	when	reintroduced	into	the	fear	conditioning	(shocking)	chamber.	Therefore,	the	rats	were	put	back	into	the	shocking	chamber	for	5	minutes	and	were	observed	for	freezing	time	and	the	amount	of	fecal	production.		
To	assess	anxiety,	the	rats	were	placed	in	an	elevated	O-maze	for	five	minutes,	measuring	the	amount	of	time	spent	in	the	open	segments	which	is	inversely	correlated	to	anxiety	level	of	the	animal	as	proposed	by	Shepherd	et	al.	(1994).	The	elevated		O-maze	(Fig.	2)	consisted	of	an	annular	platform	elevated	65	cm	above	the	floor	(105	cm	in	diameter,	10	cm	in	width),	the	platform	of	the	elevated	O-maze	was	divided	into	4	segments:	2	opposing	open	segments	with	no	walls,	and	2	opposing	closed	segments	with	walls	extending	27	cm	above	the	platform	surface.	The	O-maze	was	located	in	an	otherwise	empty	room	and	the	researcher	stepped	out	of	room	and	closed	the	door	once	rat	was	placed	in	the	open	segment	of	the	O-maze	as	to	not	distract	from	the	rats	normal	exploratory	behavior.	Behavior	was	recorded	on	video	for	later	analysis.			
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To	assess	reward-seeking	behavior,	the	rats	were	then	placed	in	the	open	field	enclosure	(Fig.	1)	for	3	consecutive	1-minute	trials,	based	on	the	reward	training	procedure.	At	the	beginning	of	each	trial,	the	rat	was	enclosed	in	a	start	box.	The	start	box	door	was	opened	and	a	Froot	Loop	(food	reward)	delivered	through	the	reward	delivery	tube.	The	time	to	retrieve	the	Froot	Loop	was	measured.	Behavior	was	recorded	on	video	for	later	analysis.			
All	behavioral	tests	were	done	twice:	week	1	(anxiety	tested	1	day	after	shock	treatment,	fear	and	reward-seeking	tested	2	days	after	shock	treatment)	and	again	in	week	2	(anxiety	tested	8	days	after	shock	treatment,	fear	and	reward-seeking	tested	9	days	after	shock	treatment).	
Statistical	analysis	
		 To	determine	significant	differences	in	behavioral	(dependent)	measures,	we	first	compared	data	from	all	four	groups	using	a	one-way	ANOVA	(VassarStats).	If	overall	significance	(p	≤	0.05)	was	found,	a	subsequent	Tukey’s	post-hoc	analysis	was	used	to	determine	significant	differences	between	individual	groups.	Standard	two-tailed	t-tests	(VassarStats)	were	used	to	analyze	changes	within	groups	between	week	one	and	two.	We	were	particularly	interested	in	the	differences	between	the	Stress	and	Stress+Oxytocin	groups	to	most	directly	address	the	objectives	of	this	study.		
The	procedures	described	in	this	proposal	have	been	reviewed	and	approved	by	the	
Eastern	Washington	University	Institutional	Animal	Care	and	Use	Committee	(effective	
June	7,	2016).	
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Results	
For	behavioral	measures	assessing	fear,	we	found	overall	significance	in	both	measures	(freezing	and	defecation),	during	both	week	1	and	week	2	(Fig.	3,	p<0.0001;	Fig.	4,	p<0.001;	Fig.	7,	p<0.0005;	Fig.	8,	p<0.05).	Freezing	time	in	seconds	was	significantly	lower	for	Control,	Oxytocin,	and	Oxytocin+Stress	groups	when	compared	to	the	Stress	group	(Fig.	3,	p<0.01)	during	week	1.	In	week	2,	the	decreased	freezing	time	between	the	Stress	group	and	the	Oxytocin	and	Control	groups	remained	significant	(Fig	7,	p<0.01)	but	the	Oxytocin+Stress	group	was	no	longer	significantly	lower	than	the	Stress	group,	or	significantly	higher	than	the	
Control	group	(Fig	7).	When	comparing	week	1	to	week	2,	the	freezing	times	for	the	
Stress	group	shows	a	significant	decrease	over	time	(Fig.11,	p<0.05)	while	this	decrease	for	the	Oxytocin+Stress	group	was	not	significant	across	the	two	weeks	(Fig.	11).	
	 Fecal	Production	(measured	in	grams	of	feces)	was	significantly	lower	for	
Control,	Oxytocin,	and	Oxytocin+Stress	groups	when	compared	to	the	Stress	group	(Fig.	4,	p<0.05)	in	week	1	after	fear	conditioning.	By	week	2	the	Stress	group	was	still	significantly	higher	than	the	Oxytocin	and	Control	groups	(Fig	8,	p<0.01)	but	the	
Oxytocin+Stress	group	was	no	longer	significantly	lower	than	the	Stress	group,	or	significantly	higher	than	the	Control	group	(Fig	8).		
	 Tests	for	anxiety	and	reward	seeking	behavior	failed	to	produce	significant	results	in	either	week	1	or	week	2	(overall	one-way	ANOVA;	Fig.	5,	p=0.15;	Fig.	6,	p=0.47;	Fig.	9,	p=0.68;	Fig.	10,	p=0.55).	
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Discussion	
	 It	is	clear	that	the	PTSD	paradigm	worked	to	induce	fear	in	the	rats	based	on	the	differences	between	the	Control	and	Stress	groups	(Fig.	3-4,	Fig.7-8).	These	results	also	supported	our	hypothesis	that	prophylactic	oxytocin	treatment	would	decrease	fear	related	behaviors	after	a	PTSD-like	stressor.	While	the	Oxytocin+Stress	group	had	increased	fear	related	behaviors	compared	to	the	Control	group,	both	the	time	spent	freezing	(Fig.	3)	and	the	amount	of	fecal	production	(Fig.	4)	were	decreased	significantly	compared	to	the	Stress	group.	However,	the	significant	difference	in	fear	related	behaviors	between	the	Stress	and	Oxytocin+Stress	groups	does	not	continue	in	the	second	week	post	stressor	(Fig.	7-8).	This	lack	of	significance	could	be	due	to	the	attenuation	of	fear	responses	over	time	in	the	Stress	group	which	decreased	from	week	one	to	week	two,	as	opposed	to	diminished	efficacy	of	the	prophylactic	treatment	in	the	Oxytocin+Stress	group,	which	also	decreased	in	fear	related	measures	but	were	not	significant	(Fig.	11).		
	 As	there	was	no	significance	in	anxiety	related	behaviors	between	the	Control	and	the	Stress	groups	(Fig.	5	and	Fig.	9),	it	appears	our	paradigm	did	not	work	for	testing	or	invoking	these	symptoms.	It	is	unclear	why	the	elevated	O-maze	did	not	produce	results	as	it	has	shown	to	be	reliable	in	other	similar	tests	of	the	PTSD-like	model	(Gao	et	al.,	2014;	Renicker	et	al.,	2015).	Gao	et	al.	(2014)	who	developed	the	PTSD-like	model	in	rats	used	an	elevated	plus-maze	to	test	anxiety	so	their	results	cannot	be	compared	directly	to	our	O-maze	results,	although	a	similar	effect	would	be	expected.	One	possible	explanation	is	the	temporal	sequence	of	testing,	Gao	et	al.	
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(2014)	performed	the	elevated	plus-maze	test	after	re-exposure	to	the	fear	conditioning	chamber	while	our	elevated	O-maze	tests	were	done	the	day	before	re-exposure.	Renicker	et	al.	(2015)	also	tested	the	elevated	O-maze	after	re-exposure	to	the	fear	conditioning	chamber,	although	there	was	a	gap	of	time	(5	days)	between	the	tests.	Previous	research	has	suggested	that	a	reminder	of	the	stress	experience	can	influence	memory	and	behavior	(Zoladz	et	al.,	2010;	Burke	et	al.,	2013).	As	such,	it	is	possible	that	the	re-exposure	to	the	fear-conditioning	chamber	enhanced	the	anxiety	response	seen	in	the	previous	studies	of	Gao	et	al.	(2014)	and	Renicker	et	al.	(2015).	
There	was	also	a	lack	of	significance	in	reward-seeking	behaviors	between	the	Control	and	the	Stress	groups	(Fig.	6	and	Fig.	10).	Since	reward-seeking	behaviors	have	not	been	analyzed	in	the	rodent	model	of	PTSD,	it	is	possible	that	these	behaviors	are	not	affected	in	rodents	as	is	found	in	human	cases	of	PTSD.	Alternatively,	since	the	reward-seeking	paradigm	used	in	this	study	was	developed	in	our	lab	as	a	cost	effective	substitute	to	the	classical	operant	box,	it	is	possible	that	these	reward-seeking	behaviors	are	impacted	in	the	rat	model	of	PTSD	but	our	dependent	measures	did	not	expose	these	effects.	If	this	experiment	were	to	be	repeated,	it	might	benefit	from	the	use	of	operant	boxes	as	has	been	used	in	previous	studies	to	assess	reward-seeking	behaviors	(Dingess	et	al.,	2017;	Piantadosi	et	al.,	2017).	
	 An	important	aspect	to	consider	is	the	timing	of	“prophylaxis”.	While	our	study	defined	prophylaxis	as	treatment	prior	to	the	traumatic	stressor,	other	studies	
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define	preventative	treatment	as	interventions	performed	soon	after	the	traumatic	event	before	symptoms	of	PTSD	manifest,	also	called	“early	intervention”	(Vaiva	et	al.,	2003;	Baker	et	al.,	2009;	Daskalakis	et	al.,	2013;	Rothbaum	et	al.,	2014;	Frijling	et	al.,	2014;	Renicker	et	al.,	2015).	Early	intervention	or	prophylactic	treatments	could	also	be	affecting	different	mechanisms	than	traditional	treatments,	such	as	memory	consolidation	(Morena	et	al.,	2017).	Future	studies	should	evaluate	the	pros	and	cons	of	each	method.	Treatment	after	the	traumatic	event	would	be	most	practical	as	the	vast	majority	of	traumatic	events	cannot	be	predicted;	however,	if	treatment	before	a	traumatic	stressor	offers	significant	protection	it	could	be	beneficial	in	settings	such	as	combat	warfare,	law	enforcement	operations,	and	surgical	settings.	
Whether	oxytocin	treatment	is	delivered	soon	after	the	traumatic	event	(Frijling	et	al.,	2014;	Renicker	et	al.,	2015;	van	Zuiden	et	al.,	2017)	or	before,	as	was	done	in	this	study,	research	suggests	that	intranasal	oxytocin	administration	provides	neuroprotection	and	attenuates	fear	related	behaviors	in	humans	(Frijling	et	al.,	2014;	van	Zuiden	et	al.,	2017)	and	rodents	(Renicker	et	al.,	2015).	The	direct	effects	of	oxytocin	on	brain	regions	that	contain	oxytocin	receptors	and	process	emotion	(e.g.,	amygdala)	are	likely	implicated	in	the	behavioral	changes	we	observed	in	the	measures	of	fear.	Furthermore,	PTSD	has	been	shown	to	alter	endocrine	output	related	to	the	HPA	axis	(reviewed	in	Daskalakis	et	al.,	2013).	Intranasal	oxytocin	administration	is	likely	impacting	the	HPA	axis	but	how	oxytocin	alters	the	HPA	axis	is	poorly	understood	(reviewed	in	Stockhorst	and	Antov,	2016).		
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Certain	factors	should	be	considered	when	designing	future	studies.	Genetics	and	epigenetics	both	play	a	role	in	the	likelihood	of	developing	PTSD	(Yehuda	&	Bierer	2009;	Gerritsen	et	al.,	2017)	as	well	as	the	potential	for	treatment	success	(Yehuda	et	al.,	2013).	Additionally,	sex	differences	are	found	to	be	very	pronounced	in	the	instances	of	PTSD	(2:1	female	to	male	ratio)	(Kilpatrick	et	al.,	2013)	and	oxytocin	efficacy	(Sack	et	al.,	2017;	Smith	&	Wang	2013).	As	our	study	population	consisted	of	only	male	rats	we	were	not	be	able	to	address	these	differences.	Many	factors	influence	the	probability	of	developing	PTSD.	In	humans,	while	approximately	80%	of	the	population	is	exposed	to	traumatic	stressors,	only	a	small	percentage	(~11%)	of	them	go	on	to	develop	the	disorder	(Kilpatrick	et	al.,	2013).	Therefore,	a	relatively	small	study	such	as	ours	may	not	see	a	large	enough	sample	of	affected	individuals	to	gain	an	accurate	representation	of	the	effects.	
	 The	results	of	this	study	suggest	that	further	testing	is	warranted	to	ascertain	whether	or	not	prophylactic	oxytocin	treatment	is	an	effective	and	practical	prevention	method	for	PTSD.	Our	fear	results	corroborate	the	findings	of	van	Zuiden	et	al.	(2017)	Friljing	et	al.	(2014)	and	Renicker	et	al.	(2015);	however,	the	impact	of	prophylactic	oxytocin	treatment	on	anxiety	and	reward	seeking	need	further	investigation.	
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Figure 1. Schematic diagram of open field enclosure and reward delivery area. 
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Figure	2.	Rat	in	the	enclosed	area	of	the	elevated	zero	maze.		
	
Figure	3.	Time	spent	motionless	(freezing)	during	5	minute	re-exposure	to	the	foot	shock	chamber	following	oxytocin	pretreatment	(n=6,	per	group)	week	one	post	stress.	Overall	significant	difference	by	ANOVA	p<0.0001	*	significantly	different	than	Oxytocin+Stress	p<0.05;		+	significantly	different	than	Control	and	Oxytocin	p<0.05	
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Figure	4.	Fecal	production	during	5	minute	re-exposure	to	the	foot	shock	chamber	following	oxytocin	pretreatment	(n=6,	per	group)	week	one	post	stress.	Overall	significance	by	ANOVA	p<0.001;	*	significantly	different	than	Oxytocin+Stress	p<0.05;		+	significantly	different	than	Control	and	Oxytocin	p<0.05	
	
Figure	5.	Time	spent	in	the	open	arm	during	5-minute	exposure	to	the	elevated	zero	maze	following	oxytocin	pretreatment	(n=6,	per	group)	week	one	post	stress.	There	was	no	significant	difference	between	the	groups	p=0.15	
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Figure	6.	Average	time	across	3	trials	to	retrieve	food	reward	(Froot	Loop)	in	open	field	enclosure	following	oxytocin	pretreatment	(n=6,	per	group)	week	one	post	stress.	There	was	no	significant	difference	between	groups	p=0.47		
	
Figure	7.	Time	spent	motionless	(freezing)	during	5-minute	re-exposure	to	the	foot	shock	chamber	following	oxytocin	pretreatment	(n=6,	per	group),	week	two	post	stress.	Overall	significance	from	ANOVA	p<0.0005	
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+	significantly	different	than	Control	and	Oxytocin	p<0.05	
	
Figure	8.	Fecal	production	during	5-minute	re-exposure	to	the	foot	shock	chamber	following	oxytocin	pretreatment	(n=6,	per	group),	week	two	post	stress.	Overall,	p=0.016;		+	significantly	different	than	Control	and	Oxytocin	p<0.05	
	
Figure	9.	Time	spent	in	the	open	arm	during	5	minute	exposure	to	the	elevated	zero	maze	following	oxytocin	pretreatment	(n=6,	per	group)	two	weeks	post	stress.	There	was	no	overall	significance	between	groups	p=0.68.	
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Figure	10.	Time	to	retrieve	food	reward	(Froot	Loop)	in	open	field	enclosure	following	oxytocin	posttreatment	pretreatment	(n=6,	per	group)	two	weeks	post	stress.	p=0.55			
	
Figure	11.	Comparison	of	freezing	times	between	week	1	and	week	2	in	Stress	and	Oxytocin+Stress	groups.		*	p<0.05	two-tailed	t-test	
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